BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie lub cytologicznie rak płuc typu drobnokomórkowego
- •Ograniczone stadium choroby potwierdzone badaniem PET przed rozpoczęciem chemioterapii
- •Ukończona chemioterapia platynowa z etopoznidem i radioterapia bez progresji choroby
- •Co najmniej 3 cykle chemioterapii
- •Dobrze funkcjonujące organy wewnętrzne i układ krwiotwórczy
- •Chęć stosowania antykoncepcji przez czas badania
✗ Disqualifies
- •Rak drobnokomórkowy spoza płuc
- •Rak duże komórki neuroendokrynne
- •Rak płuc typu drobnokomórkowego z przerzutami
- •Jednoczesne występowanie raka drobnokomórkowego i niedrobnokomórkowego
- •Ciężkie wcześniejsze reakcje alergiczne na podobne leki
- •Uczulenie na składniki leku atigotatug, nivolumab lub durvalumab
- •Zaburzenia neurologiczne obwodowe
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (34)
Southern Cancer Center
Daphne, United States
Sansum Clinic
Santa Barbara, United States
Florida Cancer Specialists - South
Fort Myers, United States
University of Miami - Sylvester Cancer Center
Miami, United States
Ocala Oncology Center
Ocala, United States
Florida Cancer Specialists - North
Orange City, United States
Cancer Care Centers of Brevard
Palm Bay, United States
Florida Cancer Specialists - East
West Palm Beach, United States
Piedmont Healthcare - Atlanta
Atlanta, United States
Illinois Cancer Specialists
Arlington Heights, United States
Illinois Cancer Care
Peoria, United States
Indiana University Simon Cancer Center
Indianapolis, United States
Baptist Health - Corbin
Corbin, United States
Baptist Health - Lexington
Lexington, United States
Baptist Health - Louisville
Louisville, United States
Minnesota Oncology Hematology
Maple Grove, United States
Missouri Cancer Associates
Columbia, United States
White Plains Hospital Physician Associates
White Plains, United States
Carolina Cancer Research Center
Wilson, United States
Oncology Hematology Care
Cincinnati, United States
The Ohio State University - Arthur James Cancer Hospital & Solove Research Institute
Columbus, United States
Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center
Columbus, United States
Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center)
Eugene, United States
Tennessee Cancer Specialists
Knoxville, United States
SCRI Oncology Partners
Nashville, United States
Texas Oncology - West Texas
Amarillo, United States
Texas Oncology- Austin
Austin, United States
Texas Oncology - Gulf Coast
Beaumont, United States
Texas Oncology - DFW
Dallas, United States
Texas Oncology - Northeast Texas
Denison, United States
Texas Oncology - San Antonio
San Antonio, United States
Virginia Cancer Specialists
Fairfax, United States
Virginia Oncology Associates
Norfolk, United States
Blue Ridge Cancer Center (Oncology & Hematology Associates of Southwest VA)
Salem, United States
Trial contact
Sarah Cannon Development Innovations, LLC
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.